GSK•benzinga•
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion
Summary
GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga